Baseline characteristics | n | % | Mean ± SD | 95% CI | Median |
Age (years) | 300 | 63.4 ± 9.0 | 62.4 - 64.4 | 64.0 | |
Men | 169 | 56.3 | |||
Women | 131 | 43.7 | |||
Body weight (kg) | 300 | 96.1 ± 17.6 | 93.1 - 98.1 | 95.0 | |
BMI (kg/m2) | 299 |
| 32.7 ± 5.4 | 32.1 - 33.3 | 31.8. |
Systolic BP (mm Hg) | 300 |
| 137.3 ± 15.1 | 135.6 - 139.0 | 136.0 |
Diastolic BP (mm Hg) | 300 | 74.0 ± 9.5 | 77.9 - 80.1 | 80.0 | |
HbA1c (mmol/mol) | 300 | 72.4 ± 10.3 | 71.2 - 73.5 | 69.5 | |
HbA1c (% DCCT) | 300 | 8.8 ± 0.9 | 8.7 - 8.9 | 8.5 | |
FPG (mmol/L) | 300 | 9.3 ± 2.8 | 8.9 - 9.6 | 8.9 | |
Creatinine (µmol/L) | 265 |
| 84.6 ± 21.6 | NA | 83.0 |
Duration of diabetes | |||||
<5 years | 65 | 22 | |||
5 - 10 years | 79 | 26 | |||
>10 years | 156 | 52 | |||
Initial dose of insulin glargine 300 U/mL | 300 | 27.1 ± 12.2 | 25.7 - 28.5 | 24.0 | |
OAD treatment | |||||
metformin | 249 | 83 | |||
sulfonylurea | 129 | 43 | |||
pioglitazone | 13 | 4 | |||
DPP-4 inhibitors | 102 | 34 | |||
glinides | 9 | 3 | |||
α-glucosidase inhibitors | 297 | 99 | |||
SGLT2 inhibitors | 37 | 12 | |||
GLP1 receptor agonists | 21 | 7 |